IL6 and Hutchinson-Gilford progeria syndrome: Specifically, specific inhibition of Il‐6 by tocilizumab demonstrated to improve inflammation and phenotype of both patient fibroblasts and mouse model of HGPS reducing the accumulation of progerin, and rescuesing the nuclear envelope and chromatin abnormalities (Squarzoni et al., 2021).